Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Sana Biotechnology Inc SANA

Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing cell engineering programs to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune and central nervous system disorders. It develops a pipeline of clinical product... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:SANA)

Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

GlobeNewswire February 29, 2024

Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference

GlobeNewswire February 28, 2024

Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP

GlobeNewswire February 13, 2024

Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire February 12, 2024

Sana Biotechnology Announces Pricing of Upsized Public Offering

GlobeNewswire February 8, 2024

Sana Biotechnology Announces Proposed Public Offering of Common Stock

GlobeNewswire February 7, 2024

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies

GlobeNewswire January 5, 2024

Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2024

Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting

GlobeNewswire December 11, 2023

Opinion & Analysis (NDAQ:SANA)

No current opinion is available.

Bullboard Posts (NDAQ:SANA)

Sana Biotechnology to Present at the Cowen 44th Annual Healt

BREAKING NEWS: $SANA Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference | BenzingaSEATTLE, Feb. 28, 2024...
whytestocks - February 28, 2024

SANA ....Implosion time ???

MOre than likely
Iseneschal - January 10, 2024

SANA ....rug pull time ; )

buh bye !
Iseneschal - January 10, 2024

SANA....better pick thst volume up or its

OVER
Iseneschal - January 10, 2024

SANA...hurry up and die

sheeszh
Iseneschal - January 10, 2024